FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895966166> ?p ?o ?g. }

• W2895966166 endingPage "e204" @default.
• W2895966166 startingPage "e203" @default.
• W2895966166 abstract "Objectives: Primary Sjogren syndrome (pSS) is a progressive autoimmune disease characterized by formation of ectopic germinal centers in exocrine glands and secretory gland dysfunction with subset of patients developing extraglandular manifestations. CFZ533 is a novel monoclonal antibody that selectively blocks CD40, a co-stimulatory pathway receptor essential for germinal center reactions and other immune-mediated functions implicated in pSS pathogenesis. We conducted a randomized, double-blind, placebo-controlled, multicentric, partial crossover, Phase IIa Proof of Concept (PoC) study to evaluate the safety, tolerability and efficacy of CFZ533 in patients with pSS." @default.
• W2895966166 created "2018-10-26" @default.
• W2895966166 creator A5000148303 @default.
• W2895966166 creator A5001643792 @default.
• W2895966166 creator A5006190744 @default.
• W2895966166 creator A5010152348 @default.
• W2895966166 creator A5015430822 @default.
• W2895966166 creator A5018441388 @default.
• W2895966166 creator A5023365520 @default.
• W2895966166 creator A5023991059 @default.
• W2895966166 creator A5024191081 @default.
• W2895966166 creator A5026025689 @default.
• W2895966166 creator A5027158845 @default.
• W2895966166 creator A5043000577 @default.
• W2895966166 creator A5044642567 @default.
• W2895966166 creator A5050503305 @default.
• W2895966166 creator A5050685588 @default.
• W2895966166 creator A5055902213 @default.
• W2895966166 creator A5065798696 @default.
• W2895966166 creator A5066726905 @default.
• W2895966166 creator A5070363670 @default.
• W2895966166 creator A5073698150 @default.
• W2895966166 creator A5075106239 @default.
• W2895966166 creator A5076875511 @default.
• W2895966166 creator A5076891691 @default.
• W2895966166 creator A5078588605 @default.
• W2895966166 creator A5078750931 @default.
• W2895966166 creator A5082669130 @default.
• W2895966166 date "2018-10-01" @default.
• W2895966166 modified "2023-10-01" @default.
• W2895966166 title "Novel Anti-CD40 Monoclonal Antibody CFZ533 in Patients with Primary Sjogren Syndrome: A Phase Iia Double-Blind, Placebo–Controlled Randomized Trial" @default.
• W2895966166 doi "https://doi.org/10.1016/j.oooo.2018.05.036" @default.
• W2895966166 hasPublicationYear "2018" @default.
• W2895966166 type Work @default.
• W2895966166 sameAs 2895966166 @default.
• W2895966166 citedByCount "3" @default.
• W2895966166 countsByYear W28959661662020 @default.
• W2895966166 countsByYear W28959661662022 @default.
• W2895966166 crossrefType "journal-article" @default.
• W2895966166 hasAuthorship W2895966166A5000148303 @default.
• W2895966166 hasAuthorship W2895966166A5001643792 @default.
• W2895966166 hasAuthorship W2895966166A5006190744 @default.
• W2895966166 hasAuthorship W2895966166A5010152348 @default.
• W2895966166 hasAuthorship W2895966166A5015430822 @default.
• W2895966166 hasAuthorship W2895966166A5018441388 @default.
• W2895966166 hasAuthorship W2895966166A5023365520 @default.
• W2895966166 hasAuthorship W2895966166A5023991059 @default.
• W2895966166 hasAuthorship W2895966166A5024191081 @default.
• W2895966166 hasAuthorship W2895966166A5026025689 @default.
• W2895966166 hasAuthorship W2895966166A5027158845 @default.
• W2895966166 hasAuthorship W2895966166A5043000577 @default.
• W2895966166 hasAuthorship W2895966166A5044642567 @default.
• W2895966166 hasAuthorship W2895966166A5050503305 @default.
• W2895966166 hasAuthorship W2895966166A5050685588 @default.
• W2895966166 hasAuthorship W2895966166A5055902213 @default.
• W2895966166 hasAuthorship W2895966166A5065798696 @default.
• W2895966166 hasAuthorship W2895966166A5066726905 @default.
• W2895966166 hasAuthorship W2895966166A5070363670 @default.
• W2895966166 hasAuthorship W2895966166A5073698150 @default.
• W2895966166 hasAuthorship W2895966166A5075106239 @default.
• W2895966166 hasAuthorship W2895966166A5076875511 @default.
• W2895966166 hasAuthorship W2895966166A5076891691 @default.
• W2895966166 hasAuthorship W2895966166A5078588605 @default.
• W2895966166 hasAuthorship W2895966166A5078750931 @default.
• W2895966166 hasAuthorship W2895966166A5082669130 @default.
• W2895966166 hasConcept C126322002 @default.
• W2895966166 hasConcept C142724271 @default.
• W2895966166 hasConcept C154317977 @default.
• W2895966166 hasConcept C159654299 @default.
• W2895966166 hasConcept C163864487 @default.
• W2895966166 hasConcept C197934379 @default.
• W2895966166 hasConcept C202751555 @default.
• W2895966166 hasConcept C203014093 @default.
• W2895966166 hasConcept C204787440 @default.
• W2895966166 hasConcept C27081682 @default.
• W2895966166 hasConcept C2778375690 @default.
• W2895966166 hasConcept C2778453870 @default.
• W2895966166 hasConcept C2780942790 @default.
• W2895966166 hasConcept C39347974 @default.
• W2895966166 hasConcept C542903549 @default.
• W2895966166 hasConcept C55493867 @default.
• W2895966166 hasConcept C71924100 @default.
• W2895966166 hasConcept C86803240 @default.
• W2895966166 hasConcept C96926380 @default.
• W2895966166 hasConceptScore W2895966166C126322002 @default.
• W2895966166 hasConceptScore W2895966166C142724271 @default.
• W2895966166 hasConceptScore W2895966166C154317977 @default.
• W2895966166 hasConceptScore W2895966166C159654299 @default.
• W2895966166 hasConceptScore W2895966166C163864487 @default.
• W2895966166 hasConceptScore W2895966166C197934379 @default.
• W2895966166 hasConceptScore W2895966166C202751555 @default.
• W2895966166 hasConceptScore W2895966166C203014093 @default.
• W2895966166 hasConceptScore W2895966166C204787440 @default.
• W2895966166 hasConceptScore W2895966166C27081682 @default.
• W2895966166 hasConceptScore W2895966166C2778375690 @default.
• W2895966166 hasConceptScore W2895966166C2778453870 @default.
• W2895966166 hasConceptScore W2895966166C2780942790 @default.
• W2895966166 hasConceptScore W2895966166C39347974 @default.

• next